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Helicobacter pylori  is a gram negative helix-
shaped bacteria which is pathogen and can live in the 
stomach, between the mucus and the epithelial mucosa.1 
Helicobacter pylori can damage the Gastroduodenal 
mucosa, causing inflammation, ulceration, MALT 
lymphoma and cancer. It was identified in 1982 by 
Australian scientists Barry Marshall and Robin Warren, 
and in 1994, the International Agency for Research on 
Cancer classified Helicobacter pylori as a carcinogen, 
or cancer-causing agent, in humans.2
Virulence factors of Helicobacter pylori, include 
Cag A, Vac A, Bab A etc, induce proinflammatory 
cytokine production and release, proliferative epithelial 
cells signaling, and epithelial damage.3,4 There are two 
possible mechanisms currently being investigated by 
which Helicobacter pylori could cause cancer. The first 
mechanism  involves the production of free radicals 
near Helicobacter pylori as well as an increased rate 
of host cell mutation.The second  mechanism involves 
enhancement of the transformed host cell phenotype 
by altering cell proteins such as adhesion proteins. So 
Helicobacter pylori causes inflammation and locally 
high levels of TNF-α and/or interleukin 6.5,6
The inflammatory changes on gastroduodenal 
mucosa caused by Helicobacter pylori infection  can be 
seen macroscopically by endoscopy examination and 
microscopiccally by histopathology examination.7,8 
Tissue damage due to free radicals can be examined by 
measuring the malondialdehyde compound.9,10
Laura Dairi et al in their study reported that from 
20 patients with Helicobacter pylori (+), the average 
level of malondialdehyde was 1.58 umol/mL while 
in 20 other patients with Helicobacter pylori (-), the 
malondialdehyde level was 1.19 umol/mL with p value 
0.013. They concluded that the mean serum levels of 
malondialdehyde  was higher in Helicobacter pylori 
positive gastritis than Helicobacter pylori negative.11 
We have some consensus and guidelines for the 
Helicobacter pylori  eradication therapy using triple 
or quadruple drug regiments.12 Some experts suggest 
that rebamipide can prevent Helicobacter pylori 
infection, reduce inflammation, accelerate healing 
after eradication, promote ulcer healing, and prevent 
progression of preneoplastic resions.13
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